Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?

被引:118
作者
Fischer, Benedikt [1 ,2 ,3 ]
Keates, Annette [4 ]
Buehringer, Gerhard [5 ,6 ]
Reimer, Jens [7 ]
Rehm, Juergen [2 ,3 ,5 ,8 ]
机构
[1] Simon Fraser Univ, Fac Hlth Sci, CARMHA, Vancouver, BC V6B 5K3, Canada
[2] CAMH, Social & Epidemiol Res Dept, Toronto, ON, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[4] Vrije Univ Amsterdam, Amsterdam, Netherlands
[5] Tech Univ Dresden, Inst Clin Psychol & Psychotherapy, D-01062 Dresden, Germany
[6] IFT Inst Therapieforsch, Munich, Germany
[7] Univ Hamburg, Ctr Interdisciplinary Addict Res, Hamburg, Germany
[8] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
Harms; health systems; international comparison; medical culture; misuse; policy; prescription opioids; ALTERNATIVE MEDICINE; PAIN MANAGEMENT; UNITED-STATES; PREVALENCE; DIVERSION; CANADA; ABUSE; POPULATION; EUROPE; MISUSE;
D O I
10.1111/add.12224
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
AimsThis paper aims to identify possible system-level factors contributing to the marked differences in the levels of non-medical prescription opioid use (NMPOU) and prescription opioid (PO)-related harms in North America (i.e. the United States and Canada) compared to other global regions. MethodsScientific literature and information related to relevant areas of health systems, policy and practice were reviewed and integrated. ResultsWe identified several but different factors contributing to the observed differences. First, North American health-care systems consume substantially more Poseven when compared to other high-income countriesthan any other global region, with dispensing levels associated strongly with levels of NMPOU and PO-related harms. Secondly, North American health-care systems, compared to other systems, appear to have lesser regulatory access restrictions for, and rely more upon, community-based dispensing mechanisms of POs, facilitating higher dissemination level and availability (e.g. through diversion) of POs implicated in NMPOU and harms. Thirdly, we note that the generally high levels of psychotrophic drug use, dynamics of medical-professional culture (including patient expectations for effective treatment'), as well as the more pronounced for-profit' orientation of key elements of health care (including pharmaceutical advertising), may have boosted the PO-related problems observed in North America. ConclusionsDifferences in the organization of health systems, prescription practices, dispensing and medical cultures and patient expectations appear to contribute to the observed inter-regional differences in non-medical prescription opioid use and prescription opioid-related harms, although consistent evidence and causal analyses are limited. Further comparative examination of these and other potential drivers is needed, and also for evidence-based intervention and policy development.
引用
收藏
页码:177 / 181
页数:5
相关论文
共 62 条
[1]   What are the public health effects of direct-to-consumer drug advertising? [J].
Almasi, EA ;
Stafford, RS ;
Kravitz, RL ;
Mansfield, PR .
PLOS MEDICINE, 2006, 3 (03) :284-288
[2]  
[Anonymous], 2011, WORLD DRUG REP 2011
[3]  
[Anonymous], 2011, ANN REP 2011 STAT DR
[4]  
Boger R, 2011, ARZNEIVERORDNUNGS RE, P261
[5]   Improving the availability and accessibility of opioids for the treatment of pain: The International Pain Policy Fellowship [J].
Bosnjak, Snezana ;
Maurer, Martha A. ;
Ryan, Karen M. ;
Leon, Marta X. ;
Madiye, Gabriel .
SUPPORTIVE CARE IN CANCER, 2011, 19 (08) :1239-1247
[6]   Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment [J].
Breivik, H ;
Collett, B ;
Ventafridda, V ;
Cohen, R ;
Gallacher, D .
EUROPEAN JOURNAL OF PAIN, 2006, 10 (04) :287-333
[7]   Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes [J].
Breivik, H. ;
Cherny, N. ;
Collett, B. ;
de Conno, F. ;
Filbet, M. ;
Foubert, A. J. ;
Cohen, R. ;
Dow, L. .
ANNALS OF ONCOLOGY, 2009, 20 (08) :1420-1433
[8]  
Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55
[9]   Misuse of Medicines in the European Union: A Systematic Review of the Literature [J].
Casati, Alicia ;
Sedefov, Roumen ;
Pfeiffer-Gerschel, Tim .
EUROPEAN ADDICTION RESEARCH, 2012, 18 (05) :228-245
[10]   Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative [J].
Cherny, N. I. ;
Baselga, J. ;
de Conno, F. ;
Radbruch, L. .
ANNALS OF ONCOLOGY, 2010, 21 (03) :615-626